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ABBREVIATIONS 
 
PIH  -    Pregnancy Induced Hypertension 
APE  -  Antepartal Eclampsia  
IPE  -  Intrapartal Eclampsia 
SGA  -  Small for Gestational Age 
AGA  -  Appropriate for gestational Age 
LGA  -  Large for gestational Age 
DB  -  Dead born 
LB  -  Live birth 
Aldo  -  α - methyl dopa 
Nife  -  Nifedipine 
Mgso4 -  Magnesium sulfate 
APH  -  Antepartal haemorrhage 
HIV  -  Human Immunodeficiency virus 
NB  -  New born 
G  -  Gravida 
Primi  -  Primigravida 
Multi  -  Multigravida 
LN  -  Labour Naturalis 
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LSCS  -  Lower segment caesarian section 
HT  -  Hypertension 
IMNCI -  Integrated management of newborn and  
    childhood illness 
AST  -  alanine aminotransferase 
ALT  -  aspartate aminotransferase 
LDH  -  lactate dehydrogenase  
BP  -  blood pressure 
CNS  -  central nervous system 
DIC  -  disseminated intravascular coagulation 
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INTRODUCTION 
 
 The maternal well being, freedom from nutritional and systemic 
disorders are essential to provide an optimal in-utero  environment for 
proper growth and development of fetus.  In general fetus is well protected 
and insulated against adverse physical, chemical, and  zoological, insults.    
Hypertensive disorders complicating pregnancy is one of those conditions 
which may jeopardize not only the maternal health but also fetal well being. 
It forms one of the deadly triad along with hemorrhage and infection. 
   
Classification  
 There are five types of hypertensive disorders complicating pregnancy   
1. Gestational hypertension (known as pregnancy induced 
hypertension) 
2. Preeclampsia  
3. Eclampsia 
4. Preeclampsia superimposed on chronic hypertension  
5. Chronic hypertension 
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TABLE – 1 
Diagnosis of Hypertensive Disorders Complicating Pregnancy1 
 
Gestational hypertension: 
 BP ≥ 140/90 mm Hg for first time during pregnancy  
No proteinuria 
BP returns to normal < 12 weeks postpartum 
Final diagnosis made only postpartum 
May have other signs or symptoms of preeclampsia, for example, epigastric 
discomfort or thrombocytopenia 
 
Preeclampsia 
Minimum criteria 
 BP ≥  140/90 mm Hg after 20 weeks gestation  
 Proteinuria ≥ 300 mg/24 hours or ≥ 1+dispstick 
  
Increased certainty of preeclampsia 
 BP ≥  160/110mg Hg 
 Proteinuria 2.0 g/24 hours or ≥ 2+dispstick 
 
Serum creatinine > 1.2 mg/dl unless known to be previously elevated 
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 Platelets < 100,000/mm3 
 Microangiopathic hemolysis (increased LDH) 
 Elevated ALT or AST 
 Persistent headache or other cerebral or visual disturbance  
 Persistent epigastric pain  
 
Eclampsia 
 Seizures that cannot be attributed to other causes in a woman with 
preeclampsia 
  
Superimposed Preeclampsia (on chronic hypertension) 
 New  onset proteinuria ≥ 300 mg/24 hours in hypertensive  
 women but no proteinuria before 20 weeks gestation  
A sudden increase in proteinuria or blood pressure or platelet count < 
100,000/mm3 in women with hypertension and proteinuria before 20 
weeks gestation  
Chronic Hypertension 
BP ≥  140/90 mm Hg before pregnancy or diagnosed before 20 weeks 
gestation not attributable to gestational trophoblastic disease 
Or 
 13
Hypertension first diagnosed after 20 weeks gestation and persistent 
after 12 weeks postpartum. 
 
Incidence and risk factors 
 Incidence varies from 8 – 10 % 
 
Risk factors:- 
1. Parity: PIH more common in nulliparous women. 
2. Race and ethnicity:  
familial tendency to the development of both  eclampsia and 
preeclampsia suggesting a genetic predisposition 
3. Complications of pregnancy: 
Preclampsia more in multiple pregnancy, hydramnios, vesicular mole 
etc 
4. Diseases complicating pregnancy: 
Risk of preeclampsia is increased in maternal diabetes, hypertension, 
and renal disorders. 
 
5.    Emotional stress and environmental factors may contribute as a    
risk factor 
6. Age>40 
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7. Genetic thrombphilias have been associated with severe 
preeclampsia 
 
Pathogenesis of preeclampsia / eclampsia 
 Normal pregnancy is characterized by a marked increase in plasma 
volume, glomerular filtration rate and renel blood flow. There is 
considerable increase in total body sodium and also an expansion of the 
extracellular blood space in which the extra sodium is located. In contrast, 
preeclampsia is characterized by a reduced volume, reduced glomerular 
filtration rate and renal blood flow. There is sodium retention and a shift of 
sodium into the arterial walls which may be a factor in the increased 
sensitivity to pressor agents in preeclampsia. 
 
 Vasospasm is basic to pathophysiology of preeclampsia and 
eclampsia. Vascular contriction causes resistence to blood flow and accounts 
for the development of arterial hypertension. It is likely that vasospasm also 
exerts a damaging effect in vessels. AngionsinII causes endothelial cells to 
contract and these vascular changes with local  
 
hypoxia of the surrounding tissues lead to hemorrhage,  necrosis and other 
end organ disturbances observed in severe preeclampsia. 
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Etiology 
1. increased ratio of thromboxane to prostocyclin 
2. abnormal trophoblast invasion 
3. cardiovascular maladaptation. 
4. increased circulating lipid peroxide which may inhibit endogenous 
       nitric  oxide 
5. endothelial cell injury 
6. vasculitis-due to circulating immune complexes 
Investigations: 
- Routine investigations done in normal pregnancy 
- Urine examination:  
- microscopic examination for the presence of casts. 
- estimation of 24 hrs urinary protein 
- Blood biochemistry: 
  Blood urea, Uric acid, Creatinine 
- platelet count 
- Liver function test       
 - Optic fundi examination 
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Complication of preeclampsia 
- Maternal mortality 
- Maternal morbidity 
a) CNS complication(eg strokes, seizures, intracerebral 
                hemorrhage, blindness) 
b) DIC  
c) Hepatic failure or rupture, pulmonary edema 
d) Abruption placenta 
e) HELLP syndrome 
- Fetal Mortality 
- Fetal morbidity 
i) IUGR 
ii) Fetal acidemia 
iii) Complications from prematurity 
Complication of eclampsia 
- Injuries 
      - cerebral hemorrhage 
- hyperpyrexia 
- renal failure 
- pulmonancy edema 
- puerperal infection, puerperal psychosis 
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- aspiration preumonitis 
Management  
Gestational hypertension: 
 BP checkup in AN clinic- If>140/90, do urine examination to look for 
proteinuria – If no proteinuria, patient is managed as an outpatient with 
frequent check up of BP and admitted if there is a rise in BP or if there is 
IUGR. 
 Antihypertensive therapy may be indicated if the diastolic BP exceeds 
100 mmHg 
Mild preeclampsia:         
- Better to hospitalize – evaluate her and the fetus 
- Rest in bed throughout the great part of the day and night – Lying   
in left  
  - lateral position to improve uterine blood flow and help in fetal 
growth. 
- Diet: Normal diet – no salt restriction 
- Diuretics: If pulmonary edema or congestive heart failure present. 
- Monitoring of mother: BP, urine, other investigations 
- Monitoring of fetus: Assessment of fetus- clinically as well as 
sonologically 
- If gestation < 37 weeks: 
 18
 
 
If diastolic BP settles & insignificant proteinuria-patient allowed to 
go        
home, continue rest, BP check up regularly, report to hospital if 
develops  
significant swelling or develops symptoms of severe preeclampsia  
- If gestation more than 37 weeks 
   If any sign of fetal compromise-labour is induced 
If no fetal compromise and the preeclampsia does not worsen- 
pregnancy continued for another week 
 
Severe eclampsia 
-Hospitalise 
- Rest 
- Normal diet 
- Antihypertensive therapy – to keep diastolic BP between 90 -100 
mmHg –         to prevent maternal complications 
- not helpful in improving perinatal outcome 
 - Drugs useful. 
  - methyl dopa 
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  - Nifedipine 
  - Hydralazine 
 
Response to treatment        
• If no worsening / improvement present/no immenent eclampsia/ 
no fetal compromise. 
• Continue pregnancy until 36w-37w under strict vigilance. 
• If material condition worsens or symptoms of imminent 
eclampsia develop – pregnancy needs to be terminated 
irrespective of gestation. 
 
Imminent eclampsia :  Management of immenent eclampsia same as 
eclampsia. 
Eclampsia: 
1. General management 
2. Control on convulsions 
3. Control of hypertension 
4. Obstetric management 
5. Early detection and management of complications 
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General management: 
• Nursed in quiet room 
• Minimal handling of the patients 
• Examination done under the effect of  a sedative 
• Vital signs monitoring, bladder catheterization, maintenance of fluid 
balance 
• Antibiotics to prevent infection 
Control  of convulsions: 
 Various regimes have been tried 
1. Magnesium sulphate: 
  Loading lose :4g of 20% MgSO4 iv over 5 mins – followed by 
10g of 50% 
                MgSO4 (5g in each buttock)  as a deep im injection. 
  If convulsions recur after 15 mins, 2 g of 50% MgSO4 is given is 
over 5 mins. 
Maintenance dose : every four hrs -5g of 50 % MgSO4 deep im 
injection into alternate buttocks. Treatment continued for 24hrs 
after delivery or the last convulsions 
whichever occurs later. 
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2. Other drugs used:          
a) Lytic cocktail 
b) Diazepam 
c) Phenytoin 
 
 
Control of hypertension: 
 Drugs – Hydralazine. Labetolol, Nifedipine 
Obstetric management: 
 Decision to deliver must be taken as soon as the condition is 
stabilized. 
- Caesarean section not necessary. 
- Serious morbidity less common in puerperium in women delivered 
vaginally. 
- Caesarean section is only done if vaginal delivery is not possible due 
to 
    some other complications such as transverse lie, cephalopelvic  
   disproportion etc. 
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Chronic HT : 
- Anti hypertensive therapy 
- Careful monitoring of pregnancy for early detection of  intrauterine 
growth 
   restriction or development of preeclampsia.  
- Chronic HT with superimposed preeclampsia – same as for 
preeclampsia. 
 
 
Prognosis in hypertensive disorders complicating pregnancy: 
Immediate:-  
 In mild cases – if diagnosed early and treated efficiently response is 
usually good – prognosis for mother and baby is favourable. 
If severe disease and neglected – they may have convulsions and prognosis 
not good for both mother and fetus 
Premature separation of placenta may occur adding to the dangers to mother 
and child. 
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Remote: 
- vascular HT in later life – 40 % 
- Recurrent preeclampsia  
 
Differential diagnosis:         
 Eclampsia : Epilepsy, hysteria, cerebral tumors, other diseases which 
give rise to convulsions. 
Chronic hypertension: 
- essential familial hypertension 
- arterial abnormalities such as renovasular HT, coarctation of aorta 
- renal disease such as glomerulohephrits, polycystic kidney  
- connective tissue disorders 
 
New treatments :          
- current data do not support the selective use of low dose asprin2  
- Antenatal calcium supplementation do not show any benefit when 
given to    healthy nulliparous women3-6 
- Supplementation of women with H/O preeclampsia or abnormal 
uterine  artery Doppler with both vitamin C and E leads to 
significant reduction in incidence  of preeclampsia7. 
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- Efficacy of  heparin therapy for the prevention of preeclampsia in 
women   with a genetic thrombophila is unknown. 
Implications for fetus and newborn :  
1) infants born to mothers with  severe preeclampsia may show 
evidence of  IUGR and frequently delivered prematurely. They may 
tolerate labour poorly   and require resuscitation. 
2) Medications used ante or intrapartum may affect the fetus. 
a) short term sequelae of hypermagnesemia – hypotonia, 
respiratory    depression. 
b) .long term administration of MgSO4 to mother – rarely 
associated   with neonatal parathyroid abnormalities   and 
other abnormalities  of calcium homeostasis 
3) Antihypertensive  medications including calcium channel blockers  
may  have  fetal effects.  Antihypertensive medications and  
magnesium sulfate generally are not contraindications to breast 
feeding. 
4) Low dose aspirin therapy does not appear to increase the incidence 
of intracranial hemorrhage, asymptomatic bruising, bleeding from 
circumcision   sites or persistent pulmonary hypertension. 
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5) About one third of infants born to mothers with preeclampsia  have   
decreased platelet counts at birth but the counts generally increase rapidly to   
normal levels. About 40 – 50 % of newborns have neutropenia, that 
generally    resolves before 3 days of age.  These infants may be at increased 
risk of   neonatal infection. 
   
Key points:  
1. Hypertensive disorders in pregnancy include gestational or PIH, 
preeclampsia, eclampsia and chronic HT with or without 
superimposed preeclampsia. 
2. Vasospasm is  a contributing factor in the pathogensis of  
preeclampsia and pathological changes may be seen liver, kidney 
and brain. 
3. Eclampsia is a serious condition necessitating prompt management 
of convulsions and expediting delivery of fetus. 
4. Magnesium sulphate has proved to the effective in controlling 
convulsions in eclampsia and is the preferred line of therapy.8-12 
5. Eclampsia can be prevented if preeclampsia is diagnosed early and 
managed effectively 
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REVIEW OF LITERATURE 
 
Lucyc chapel, et al conducted a randomized  trial on the effect of 
antioxidants on the occurrence of pre-eclampsia in women at increased risk. 
 Oxidative stress has been implicated in the pathophysiology of pre-
eclampsia. This randomized controlled trial investigated the effect of 
supplementation with vitamins C and E in women at increased risk of the 
disorder on plasma markers of vascular endothelial activation and placental 
in sufficiency and occurrence or pre-eclampsia.  
 In this randomized controlled trial, supplementation throughout the 
second half of pregnancy with vitamins C and E in women at increased risk 
of pre-eclampsia had significant beneficial effects on biochemical markers 
of the disease, and there was a significant reduction in the proportion of 
women with pre-eclampsia. 
 The doses of vitamin C and vitamin E chosen for the study resulted in 
significant increases in plasma concentrations of ascorbic acid and α-
tocopherol. There are no reported contraindications of supplementation with 
vitamin C and E in pregnancy. Vitamin E is reported not to have any 
detrimental effects on preterm neonats or pregnant women. Numbers of 
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adverse perinatal outcomes were small in this study, but were similar in the 
two groups.  
 Antioxidants have been proposed as a potentially advantageous 
prophylactic measure for pre-eclampsia37 Two previous studies of vitamin 
supplementation, both in women with established severe early-onset pre-
eclampsia reported no substantial clinical benefit; Stratta and colleagues38 
used 100-300 mg/day vitamin E in a non randomized trial, and Gulmezoglu 
and colleagues39 used 1000 mg/da used 1000 mg/day vitamin C, 800 IU/day 
vitamin E and 2000 mg/day allopurinol in a randomized controlled  trial. 
However, Gulmezoglu and colleagues39 reported a treatment toward later 
delivery in the treated group. Since later intervention may have precluded 
maximum benefit, both reports proposed earlier initiation of therapy. 
Interpretation 
  
Supplementation with vitamins C and E may be beneficial in the 
prevention of pre-eclampsia in women at increased risk of the disease. 
Multicentre trials are needed  
to show whether vitamin supplementation affects the occurrence of pre-
eclampsia in low-risk women and to confirm the results in larger groups of 
high-risk women from different populations. 
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RICHARD  L.  NAEYE, M.D. 
Hershey, Pennsylvania 
EMANUEL A.  FRIEDMAN,  M.D. 
Boston, Massachusetts 
This study determined the frequency of the individual placement and 
fetal disorders responsible for the excessive perinatal mortality rate 
associated with gestational hypertension and proteinuria.  In a large 
prospective study of pregnancy 3.2 per cent of the mothers were classified as 
hypertensive when one4 or more measurements of gestational diastolic 
blood pressure were 85 mm. Hg or more and proteinura was 1+ or greater.  
The perinatal mortality rate for these pregnancies was 37.9 per 1,000 births 
compared with 17.2 per 1,000 for normotensive gestations without 
proteinuria.  Forty – two per cent of the total excess perinatal mortality rate 
in the pregnancies complicated by hypertension was due to large placental 
infarcts, 15 per cent to placental growth retardation, and 13 per cent to 
abruption placenta.  Both the frequency of occurrence and perinatal 
mortality rate increased for each of these disorders with increasing maternal 
blood pressures. 
It has long been known that perinatal mortality rates increase with 
material hypertension and proteinuria in pregnancy.1-3 
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A. SIVERSTONE, et al study on maternal hypertension and 
intrauterine fetal death in mid – pregnancy  
Suggested that maternal hypertension predisposes on intrauterine fetal death 
in the mid-trimester of pregnancy as it does in the third trimester. 
 Page and Christian son (1976) found that, in a series of  over 14000 
pregnancies, there was a direct correlation between maternal blood pressure 
in the mid-trimester and both the stillbirth rate and the intrauterine growth 
retardation rate. 
 
E.D.M. GALLERY, et al conducted a study on predicting the 
development of pregnancy – associated hypertension the place of 
standardized blood-pressure measurement. 
 While this is by no means an absolutely certain method of 
distinguishing patients who will become hypertensive in late pregnancy, it 
demonstrates that an at- 
 
risk group can be detected in early pregnancy, and these patients could then 
be scrutinized more closely throughout pregnancy. 
 C.W.G. REDMAN, et al conducted a study on fetal outcome in trial of  
antihypertensive treatment in pregnancy. 
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 Active treatment was associated with a significantly improved fetal 
outcome, due in part to a reduced number of mid-pregnancy abortions. 
 Hypertensive treatment had no effect on fetal growth in utero.  The 
better outcome associated with treatment was not due to the prevention of 
pre-eclampsia, and may be party due to a direct or indirect effect of 
methyldopa on uterine activity.  Methyldopa is safe to use for the treatment 
of hypertension in pregnancy in the context of the medical and obstetric 
supervision.  
 D.R. HALL, et al conducted case serious study to determine whether 
prophylactic magnesium sulphate is necessary to prevent eclampsia and 
associated complications among women with pre-eclampsia prior to labour. 
 Eclampsia remains a complex and partially understood disease.  
Currently prophylaxis I the area of greatest controversy.  Although 
magnesium sulphate is a proven anticonvulsant in the management of 
eclampsia its role in prophylaxis remains to be determined.  In our study of 
high risk patients in whom blood pressure control was carefully applied but 
magnesium sulphate not given, the rate of eclampsia was low and eclampsia 
did not appear to worsen the prognosis for mother or fetus. 
 E.J. COETZEE, et al conducted a randomized controlled trial of 
intravenous magnesium sulphate versus placebo in the management of 
women with severe pre – eclampsia. 
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Conclusion: The use of intravenous magnesium sulphate in the 
management of women with severe pre-eclampsia significantly reduced the 
development of eclampsia. 
 
 Evidence was based on large descriptive  studies such as those of 
Pritchard and the small controlled studies comparing magnesium sulphate to 
phenytoin or diazepam. 
 Sibai advocated the use of magnesium sulphate even in cases of 
moderate pre-eclampsia, while Redman maintained that anti-convulsants 
were only indicated if eclampsia occurred. 
 Lucas et al conducted a prospective study comparing  magnesium 
sulphate to phenytoin in the prevention eclampsia. 
 In their study no woman receiving magnesium sulphate developed 
eclampsia while 10 women randomized to the phenytoin group hand 
convulsions (P=0.0004) 
 This study show that intravenously administered magnesium sulphate 
in the dosage used is effective in reducing the incidence of eclampsia in 
women with severe pre-eclampsia.  However, the routine use of magnesium 
sulphate in all cases of pre-eclampsi is not justified. 
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 RICHARD  J. LEVINE, et al conducted a study on trial of  calcium to 
prevent preeclampsia. 
 In summary, supplementation with 2 g of calcium per day did not 
reduce the incidence of preeclampsia, pregnancy-associated hypertension, or 
important maternal and perinatal complications of pregnancy in nulliparous 
women.  Moreover, supplementation did not appear to prevent adverse 
pregnancy out-comes in adolescents or in women with low baseline dietary 
calcium intakes or urinary calcium excretion. The results do not support the 
use of calcium supplementation to prevent preeclampsia in healthy 
nulliparous women. 
 STEVE CARITIS, M.D., conducted a study on low dose aspirin to 
prevent preeclampsia in woman at high risk. 
 Low-dose aspirin did not prevent preeclampsia in pregnancy women 
at risk for the disease. 
 However, aspirin did not effect the mothers or neonates adversely. 
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JUSTIFICATION OF THE STUDY 
 
• Hypertensive complicating pregnancies have a greatest negative 
impact on fetal and newborn outcome. 
• Incidence of morbidity and mortality in fetus and  newborn has 
come down due to effective implementation of national health 
programmes. 
• Government has implemented first referral unit  for antenatal, 
natal and postnatal and neonatal care which may have a positive 
impact on the fetal and newborn outcome. 
• Government has recently introduced comprehensive emergency 
obstetric and newborn care centre(CEMONC) at Taluk 
headquarters, district headquarters and medical colleges to give a 
health care for pregnant mother and children. 
• More recently Government is implementing integrated 
management of newborn and childhood illnesses (IMNCI) care 
for newborn and children. 
• Increasing media awareness, increasing literacy into among 
general population and increasing socioeconomic status of the 
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people has created health awareness among people and also lot of 
changes has taken place in political and socioeconomic front.  
• These all factors are reducing the morbidity and mortality in 
newborn. 
• Most of the studies in the field of  fetal outcome in hypertensive 
complicating pregnancies, in India, have been done very rarely . 
• In this background, it is decided to study the fetal outcome in 
mothers with hypertensive disorders complicating pregnancy. 
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AIM OF THE STUDY 
 
To assess the fetal outcome in mothers with hypertensive disorders 
complicating pregnancy. 
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MATERIAL AND METHODS 
 
Study design           Case - control study 
Study Place         This study was conducted in the Department of 
Obstetrics and Gynaecology and Department of 
paediatrics, Government Raja Mirasdar Hospita, 
Thanajvur attached to Thanjavur Medical College, 
Thanjavur. 
Study Period August 2005 to July 2006  
Study Population  
 Inclusion Criteria 
 - Pregnant mothers with hypertensive complicating disordors for "case  
group study"  
 - Pregnant mothers with no hypertensive complicating disorders for  
   "control group" study 
 
 Exclusion criteria 
 - Pregnant mothers who did not turn up for follow up 
 -  Pregnant mothers who were not delivered during the study period 
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STUDY MANOEUVRE 
 
 Pregnant mothers attending the outpatient department and got 
admitted in Department of Obstetrics and Gynaecology were given a 
preformed questionairre and it was explained to them and prior consent got 
to proceed with the study.  The mothers were questioned regarding parity, 
prior history of any associated illnesses and prior hypertensive disorders 
complicating pregnancy.  They were examined regarding age, height, 
weight, associated symptoms and signs, and blood pressure recorded.  
Pregnant mothers with  hypertension were taken for case study and pregnant 
mothers with mo hypertension were taken for control group of study.  The 
mode of treatment with anti-hypertensives and the method of delivery were 
noted.  They were followed till puerperium.  The  babies born to them were 
examined and documented. 
 
 The results were analysed using  z test or Normal test and x2-test. 
(Annexure-1) 
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OBSERVATIONS 
 
 
The study was conducted among mothers with hypertensive disorders 
of pregnancy and for case comparison control group selected with mothers 
haring no hypertensive disorders of pregnancy.  In this study there were 628 
cases and 658 controls 
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CHART-2 
 
DATA  
 PIH Cases Control Group 
Pregnant Mothers 628 658 
Twin Pregnancies 17 2 
Triplets 1 - 
Births 647 660 
Live Births 530 615 
Dead Born 117 45 
Mother Expired 5 - 
Newborn Death 20 17 
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CHART - 3 
AGEWISE DISTRIBUTION OF STUDY POPULATION 
 
AGE 
<20 years 
(%) 
20-35 years 
(%) 
>35 years 
(%) Total (%) 
CASES 24 (3.4) 595 (94.8) 9 (1.4) 628 (100) 
CONTROL 
GROUP 
25 (3.8) 627 (95.3) 6 (0.9) 658 (100) 
Total     1286 
 
 
 595 (94.8%) Cases were in between 20-35 years,   24(3.4%) Cases 
were less than 20 years, and 9 (1.4%) Cases were above 35 years.  Among 
controls – 627 mothers (95.3%) were in between 20-35 years, 25 (3.8%) 
mothers were less than 20 years and 6 (0.9%) were more than 35 years 
(Table – 2) 
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CHART -4 
 
TYPE OF DIAGNOSIS OF CASES 
 
PARITY New (%) Recurrent (%) Chronic HT with 
superimposed P 
IH (%) 
Total 
Primi 374 
(59.6) 
- - 374 
(59.6) 
Multi 219 
(34.9) 
26 (4.1) 9 (1.4) 254 
(40.4) 
Total 593 
(94.5) 
26 (4.1) 9 (1.4) 628 
(100) 
 
 The primigravida and multigravida group of case group was analysed 
depending upon occurrence of hypertensive complicating pregnancies of the 
total of 628 cases. 
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- There were 374 (59.6%) cases in primigravida group that was 
newly diagnosed. 
- There  were 219 (34.9%) new cases, 26 (4.1%) recurrent cases, and 
9 (1.4%) chronic hypertension with superimposed PIH cases in the 
multigravida group. 
- There was no chronic hypertension with superimposed PIH cases 
in the primigravida group. 
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CHART - 5 
 
MONTH OF  DIAGNOSIS OF CASES 
 
 
MONT
H 
NE
W 
RECURREN
T 
CHRONIC HT 
WITH 
Superimposed PIH 
Total 
3 - - 1 1 
4 - - 4 4 
5 1 1 - 2 
6 18 1 - 19 
7 33 2 - 35 
8 27 7 - 94 
9 87 13 - 452 
10 439 2 - 17 
Others - - 4 4 
Total 593 26 9 628 
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 Hypertensive complicating pregnancies were analyzed depending 
upon the time of diagnosis of the cases into newly diagnosed at the present 
pregnancy, recurrent hypertensive complicating pregnancies with the time of 
diagnosis at the present pregnancy and chronic hypertension with 
superimposed PIH. 
 
 This study was statistically analyzed where  
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CHART - 6 
MONTH OF DIAGNOSIS OF CASES AND THEIR  
FETAL OUTCOME 
 
 ≤ 7 m        >7m       P 
value  
   ≤ 7 m           >7m P value 
 
 
LB (%) LB (%) DB DB 
CASES 
 
29 
(46.8) 
501 
(85.6) 
< 0.05 
33 
(53.2) 
84 
(14.4) 
< 0.05 
 
 
 Fetal outcome was analysed in PIH cases between before third 
trimester diagnosed mothers and mothers diagnosed during third trimester. 
 This was statistically analysed. 
 Livebirths between less than or equal to 7 months of diagnosis and 
more than 7 months of diagnosis of cases are highly significant (P <0.05) 
 There is a significant difference in deadborn babies between ≤ 7 
months and > 7 months of diagnosis of cases (P<0.05) 
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CHART - 7 
TYPE OF DIAGONSIS IN RELATION TO CASE 
SEVERITY 
 Mild Severe APE IPE 
Primi 239 95 36 4 
Multi      
New  141 57 21 0 
Recurrent  14 12 0 0 
Chronic  7 2 0 0 
 
 
 In primigravida all are new cases whereas in multigravida there were 
new cases, recurrent cases and chronic HT with superimposed PIH.  There 
were no chronic HT with superimposed PIH. 
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CHART - 8 
GRAVIDA ASSESSMENT IN STUDY POPULATION  
 PIH 
Cases % 
 
CONTROL 
Cases % 
 
Primi 374 59.6 314 47.7 
G 2 129 20.5 238 36.1 
G 3 91 14.5 83 12.6 
G 4 26 4.1 17 2.6 
G 5 6 1 5 0.8 
G 6  & above 2 0.3 1 0.2 
 
  Case group and control group were analysed depending upon 
the gravida into primigravid, G2, G3, G4, G5, G6 and above groups. 
  There were 374 cases (59.6%) in case group and 314 mothers 
(47.7%) in control group.  Secondgravida was 129 (20.5%) in PIH group 
whereas 238 (36.1%) mothers in control group 91 (14.5%) cases and 83 
(12.6%) mothers in controls were third gravida.  26 (4.1%) cases and 17 
(2.6%) controls were in the fourth gravida. 6 cases (!%) and 5 (0.8%) 
controls were in the fifth gravida.  Sixth and above gravida were (2 0.3%) in 
cases and 1 (0.2%) in controls. 
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CHART - 9 
FETAL OUTCOME IN RELATION TO GRAVIDA 
 
Cases  Primi  G2 G3 G4 & above Total  
 LB DB LB DB LB DB LB DB LB DB 
PIH 330 56 106 25 70 26 24 10 530 117 
Control  297 20 228 14 72 6 18 5 615 45 
Total           
 
 In this study, outcome of babies were analysed between different 
gravidas.  Gravidas are divided into primigravida, G3, G3 and ≥  G4 group. 
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CHART - 10 
SEVERITY OF CASE GROUP 
Category Numbers % 
Mild 401 63.1 
Severe 166 26.4 
APE 57 9.1 
IPE 4 0.6 
Total 628 100 
 
 Hypertensive complicating pregnancy group were segregated 
depending upon the severity into mild, severe, APE, and IPE cases.  There 
were 401 mild cases (63.1%), severe group was 166 (26.4%), APE 57 
(9.1%), cases and IPE 4 cases (0.6%). 
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CHART - 11 
SEVERITY OF CASE GROUP IN RELATION TO 
GRAVIDA 
 
PIH Primi Multi  P value 
Mild 239 162 > 0.05 
Severe 95 71 > 0.05 
APE 36 21 > 0.05 
IPE 4 -  
 
Severity of PIH cases occurring during primigravida and multigravida 
was compared. 
 Between mild groups there is no significant difference (P > 0.05) 
 There is insignificant difference between the severe cases 
  (P > 0.05) 
 There is no significant difference between the APE cases  
(P > 0.05) 
 χ2 = 0.4937 
χ2  with 2 d.f. at 0.05 level = 5.991 There is no significant association 
between PIH and its severity. 
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CHART - 12 
FETAL OUT COME OF CASES IN RELATION TO 
SEVERITY 
 
 LB DB 
Mild 376 39 
Severe  126 44 
P valve < 0.05 >0.05 
APE 31 26 
IPE 3 2 
 
 The case group was segregated depending upon the severity of the 
hypertensive complicating pregnancies into mild, severe, APE and IPE cases 
and the fetal outcome was analysed. 
 Life birth between mild group and severe group are highly significant  
( P < 0.0.5) 
 There is no significant difference between mild and severe cases in 
relation to dead born babies ( P > 0.05) 
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CHART – 13 
FETAL OUT COME IN STUDY POPULATION 
ASSOCIATED WITH RISK FACTORS 
 LB (%) DB (%) 
PIH 132 ( 80.5 ) 32 ( 19.5 ) 
Control 79 ( 94.1 ) 5 (5.9 ) 
P Value < 0.05 < 0.05 
 
NOT ASSOCIATED WITH RISK FACTORS 
 LB (%) DB (%) 
PIH 398 ( 82.4 ) 85 ( 17.6 ) 
Control 536 ( 93.1 ) 40 (6.9 ) 
 
 Cases and controls were analysed between live births and dead births 
depending upon presence or absence of  risk factors.  
 Out of 164 births in mothers with PIH associated with other risk 
factors, there were 132 (80.5%) were live births and 32 (19.5%) were dead 
born.  Out of 84 births in control group associated with risk factors there 
were 79 (94.1%) live births and 5 (5.9%) dead born. 
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When not associated with other risk factors compared, there were 398 
(82.4%) live births and 85 (17.6%) dead born in case group whereas in 
controls out of 576 births, 536 (93.1%)  were born alive and 40 (6.9%) were 
born dead. 
 There is a significant difference in livebirth and dead born babies on 
comparing between cases and controls with associated illness. 
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CHART -14 ASSOCIATED ILLNESS AND ITS OUTCOME IN 
STUDY POPULATION 
PIH CONTROL RISK 
FACTORS LB DB Total LB DB  Total 
Age 
(<20 >35) 
27 7 33 29 2 31 
Elderly primi 
≥ 30yr 
22 2 21 13 3 16 
Multiple 
Pregnancy 
33 4 18 4 - 2 
Anemia 37 5 36 4 2 6 
Abnormal 
Presentation 
18 4 22 9 2 11 
Hydramnios 8 2 10 8 1 9 
Chroni sys 
illness 
2 2 4 - - - 
APH 10 10 20 1 - 1 
Short stature 3 - 3 3 - 3 
Heart disease 2 - 1 3 1 4 
HIV + ve - - - 2 - 2 
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 The case group and control group were analysed depending upon 
other associated risk factors and their impact on fetal outcome.  The risk 
factors taken into account were age group < 20 yrs and more 35 yrs, 
primigravida with 30 yrs and above, multiple pregnancies ( like twins, 
triplets), anemia, abnormal presentation  like breech, persistent occipito 
posterior  
 
 oligohydramnios and polyhydramnios, chronic systemic heart diseases (like 
rheumatic heart disease, dilated cardiomyopathy) and mothers with HIV 
positive cases.  
 There is a significant difference in live born babies between case and 
control groups (P< 0.05) 
 There is  a significant difference in dead born babies between case and 
control group. 
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CHART - 15 
DRUGS RECEIVED IN CASE POPULATION 
Type of PIH Aldo Aldo./ 
Nife 
Aldo / Nife / 
MgSO4 
Others  Total 
MILD 224 118 2 57 401 
SEVERE 24 110 15 17 166 
APE 7 9 34 7 57 
IPE - 1 - 3 4 
TOTAL 225 238 51 84 628 
  
 Cases were separated into mild, severe, APE and IPE cases. There 
were no PPE cases.  They were analysed depending upon the treatment they 
received as aldo group, aldo +Nife group, aldo + nife + MgSO4 and treated 
with other modes of drugs. 
 Of 401 mild cases, 284 cases were treated with aldo alone, 118 cases 
with aldo +Nife, 2 cases with aldo +nife+ MgSO4, and 57 cases were treated 
with other mode of treatment. 
 Of 166 severe cases, 24 were treated with aldo alone, 110 were treated 
with aldo+nife, 15 cases were treated with aldo+nife+ MgSO4 and 17 cases 
were treated with other modes of treatment. 
 57
 Of APE cases, 7 were treated with aldo alone, 9 were treated with 
aldo+nife, 34 were treated with aldo+nife++MgSO4 and 7 were treated with 
other modes of treatment. 
 Of 4 IPE cases, 1 was treated with aldo+nife whereas 3 were treated 
with other modes of treatment.  
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CHART – 16 
FETAL OUTCOME IN RELATION TO DRUGS RECEIVED 
IN CASE POPULATION 
 
 Aldo Aldo/Nife Aldo / nife / + MgSO4 others 
 LB DB LB DB LB DB LB DB 
Mild 213 23 108 11 3 0 52 5 
Severe 17 6 87 28 11 6 11 4 
APE 6 1 5 4 13 21 7 0 
IPE 0 0 1 1 0 0 2 1 
  
 The fetal outcome was assessed depending upon the treatment 
received in various types of PIH. They were separated into aldo only, 
aldo+nife, aldo+nife+ MgSO4 and other modes of treatment and the 
livebirths and deadborn noted. 
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CHART - 17 
FETAL OUTCOME IN RELATION TO  
TYPE OF DELIVERY IN STUDY POPULATION 
 
 LN LSCS ‘P’ value LN LSCS ‘P’ value
 LB LB  DB DB  
PIH 361 169 <0.05 98 13 >0.05 
Control 483 132 <0.05 45 - <0.05 
  
 The case group and control group were analysed depending the 
method of delivery and its effect on fetal outcome statistically analysed. 
 There is a significant difference in LN and LSCS in live-birth babies 
both in PIH group and control group (p value for both < 0.05) 
 There is no significant difference between LN and LSCS method of 
delivery in dead-born  babies in PIH cases (p>0.05) whereas there is a 
significant difference between LN and LSCS method of delivery in dead-
born babies control group (p<0.05) 
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CHART - 18 
FETAL OUTCOME WITH MATURITY IN STUDY POPULATION 
Maturity Preterm Term Postterm Others 
Gestationa
l Age 
SGA AGA LGA SGA AGA LGA SG
A 
AGA LGA   
Outcome L
B 
D
B 
L
B 
DB L
B 
D
B 
L
B 
D
B
LB D
B
LB DB L
B
D
B
LB D
B
LB DB LB D
B 
PIH Cases 4
4 
42 4
7 
24 1
3 
1 10
0 
1
7 
30
2 
9 21 0 1 5 2 3 0 0 0 16
Control 
group 
1 2 1
0 
5 0 0 69 5 51
8 
6 17 0 0 0 0 0 0 0 0 27
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Maturity with gestational age of babies born to case group of mothers and 
control group of mothers was analysed. Highly significant difference of 
preterm babies born to mothers with PIH and with no PIH – p value is < 
0.05. There is highly significant difference of term babies between  case 
and control groups.                                                                                                      
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The observations are made with regard to age distribution, chronicity 
of PIH, severity of PIH in relation to chronicity, impact of diagnosis before 
or during third trimester on fetal outcome, occurance of PIH cases with 
regard to gravida and its relation with fetal outcome, severity of PIH in 
relation to gravida, severity of PIH and its relation to outcome of babies, 
associated illnesses and risk factors and its effect on fetal outcome, treatment 
of various types of PIH cases with various drugs, and its effect on fetal 
outcome, the method of delivery and its impact on fetal outcome, the 
methods of delivery and its impact on fetal outcome, outcome of babies with 
regard to severity of the PIH, and maturity of the babies born to PIH 
mothers. 
 
 The case group was compared with control group in relation to age 
distribution, gravida, and its outcome, associated illness and its outcome, 
method of delivery and its impact on fetal outcome and outcome of babies 
with regard to maturity of the babies. 
  
Statistical analysis was made using   z   test or normal test and   x2   test. 
Results are highly significant when new cases are compared with recurrent 
cases, outcome of live birth between mild PIH group and severe PIH group, 
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live birth of babies of PIH mothers in relation to type of delivery live birth 
and dead born of control group in relation to type of delivery, preterm babies 
in relation to PIH and control group and term babies in relation to PIH and 
control group. 
 Statistically the following analysis were of no significance.  
1)  Outcome of dead born babies in PIH mothers in relation to type of  
delivery. 
2)  No significant or insignificant in relation to primigravida or  
multigravida between mild group, severe group and APE  group. 
3) No significant in relation severity of PIH mild and severe group with 
dead born babies.  
4) No significant association between PIH severity and gravida. 
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VARIOUS ANALYSES ARE MADE BY Z TEST (OR) NORMAL 
TEST AND  χ2− test 
 
Z – Test (or) Normal test 
Test of Significance for difference between proportions 
    H0 : ρ1 = ρ2 
 
 
         ρ1 = ρ2 
  Z =   ______________   ∼ Ν(0,1) 
    
     √ P Q ( 1/n1 + 1/n2) 
 
                n1 p1 + n2  p2 
Where   ρ1 =  x1/n1 ,  ρ2 =  x1/n1,   P =   __________ 
                                                                n1  + n2   
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χ2− test 
---------- 
 
  
H0 : The two attributes are independent. 
 
               m    n   (Oi j – Ei j)2 
  χ2  =  Σ    Σ    −−−−−−   ∼ χ2 (m-1) (n-1) d.f 
         i =1    j = 1    Ei j 
 
                               m i  X  n j 
  where   Ei j =    --------------- 
                                          N 
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DISCUSSION 
 
 Maternal  well-being, freedom from nutritional and systemic in-utero 
environment for proper growth and development of fetus.Hypertensive 
complicating disorders of pregnancy are one of those conditions which may 
jeopardize not only the maternal health life but also fetal well-being. It forms 
one of the deadly triad along with hemorrhage and infection. 
 
 This study was conducted among 628 mothers who had hypertensive 
recorders complicating pregnancy and compared with 660 mothers who did 
not have hypertensive disorders complicating pregnancy.The fetal outcome 
was assessed between the two groups. 
 
 In case group, there were 530 livebirths (81.9%) out of 647 births, 
whereas in control group there were 615 livebirths(93.2%) out of 660 births. 
The percentage of deadborn babies in case group was (18.1%) whereas in 
control group it was only 6.8%. Moreover there were 5 maternal deaths in 
case group with no deaths in control  
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group. These data indicate that both maternal and fetal mortality were higher 
in case group showing the significance of the hypertensive disorders 
complicating pregnancy in maternal and fetal outcome. (Refer chart 2). 
 
 In this study, maximum number of mothers were in the age group 
between 20-35 years and there is no significant change between case 
group(94.8%) and control group(95.3%) in this age group. This may be due 
to predominant incidence of pregnancies in this age group(Refer chart 3) 
  
Maximum number of PIH mothers were newly diagnosed (94.5%) ie 
593 cases out of 628 cases, but still recurrent PIH case group were present 
26(4.1%). This suggests lack of awareness in diagnosing PIH cases. There 
were only 9 cases (1.4%) of chronic HT with superimposed PIH and there 
were no gestational induced hypertension cases. This implicates the 
importance of following of gestation induced hypertension cases and chronic 
hypertension cases which leads to superimposed preeclampsia cases( Refer 
chart 4) 
 
 Among the PIH group comparing the month of diagnosis, most of the 
mothers were diagnosed in third trimester only both in new cases 
541(91.2%) out of 593 cases and in recurrent PIH cases 22(84.6%) out of 26 
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cases. This further confirms the need of awareness in diagnosing the PIH 
cases(refer chart 5) 
 
There is a significant increase in dead-born babies 33(53.2%) out of 
62 births in PIH mothers diagnosed before third trimester, whereas live-
births were more in the PIH mothers diagnosed after 7 months of 
amenorrhea 501(85.6%) out of 585 births in this group. This suggests that 
more number of months between diagnosis and delivery leads to greater 
negative impact on fetal outcome. This may be due to the effect of the 
hypertensive disorder in producing various deleterious effects on placenta 
and fetus-showing more period of exposure leads to more deleterious effect 
(refer chart 6) 
 
 Mild PIH cases were more when mothers are newly diagnosed 
(primigravida-new 239(63.9%) out of 374 cases in the primigravida group; 
multigravida-new 141(64.4%) out of 219 multigravida new cases) whereas 
severe PIH cases were more  
 
in recurrent PIH mother 12(46.1%) in relation to mild cases 14(53.9%), 
suggesting the increased severity of the disorder in recurrent PIH group 
(Refer chart 7) 
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 Occurrence of PIH cases were more in primigravida mothers 
374(59.6%) out of 628 cases whereas there were only 254 cases(40.4%) in 
all other gravidas totaled. Moreover, when both primigravida and second 
gravida were added there were 503 cases(80.1%) in PIH gravida group. This 
may suggest the increased occurrence of PIH cases in the initial pregnancies 
but when it was compared with control group primigravida mother were 
314(47.7%) and second gravida were 238(36.1%) totaling (83.8%) which is 
almost equal to PIH case group(80.1%). This suggestion may be noted when 
assessing the increased risk of PIH cases in nulliparous women. 
(Refer.chart- 8) 
 
 Out of 386 births in PIH mothers with primigravida the dead-born 
were 56(14.5%) whereas in control group the dead-born were 20 (6.3%). 
The dead-born babies in second gravida were 25(19.1%) whereas in control 
group the dead-born  
 
were 14(5.8%). In third gravida, the deadborn babies in PIH were 26(27.1%) 
whereas in control group, the deadborn in PIH group were 10(29.4%) and in 
control group the deadborn were 5(21.7%). These data show that the 
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deadborn babies were significantly higher in PIH group compared to control 
group. (refer chart 9) 
 
 When comparing between primigravida and multigravida mild cases 
were 239(59.6%) in primigravida, severe cases were 95(57.2%) in 
primigravida, severe cases were 95(57.2%) in primigravida antepartal 
eclampsia cases were 36(63.1%) in  
 
primigravida intrapartal eclampsia cases were 4(100%) in primigravida. This 
data shows there is no significant difference between primigravida and 
multigravida. In  
 
mild, severe and antepartal eclampsia cases. The p values were >0.05 in all 
these groups (refer chart 10) 
 
 One of 628 cases, mild cases were more in number 401(63.1%) and 
severe cases were 166(26.4%). The antepartal and intrapartal eclampsia 
cases totally were 61(9.7%). This shows preeclampsia cases are more 
common than eclampsia cases (refer chart 11) 
 Comparing the outcome of babies, dead-born babies were more 
common in severe preeclampsia 44(25.9%) antepartal eclampsia 26(45.6%) 
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and in intrapartal eclampsia 2(66.7%) whereas in mild preeclampsia cases 
the deadborn were 39(9.4%). This shows that with increasing seventy of the 
PIH cases, the dead-born babies were more in number. (refer chart 12) 
 
 There is little increase in dead-born babies when there are other 
associated risk factors as dead-born babies in PIH mothers with associated 
risk factors were 32(19.5%) whereas PIH without other risk factors they 
were 85(17.6%) (refer chart 13) 
 When mild cases were treated with alpha methyl dopa only the dead-
born babies were 23(9.7%) whereas treatment with aldo+nifedipine showed 
11(9.2%)  
 
showing no difference between treating the mild cases with alpha methyl 
dopa only or alpha methyl dopa and nifedipine. 
 When severe cases were treated with alpha methyl dopa only the 
deadborn were 6(26%) while treatment with alpha methyl dopa +nifedipine 
the deadborn were 28(24.3%) and treatment with aldo+nife+MgSO4 the 
deadborn were 6(35.2%). This also shows that there is no significant 
variance between treating the severe cases with alpha methyl dopa  only, or 
alpha methyl dopa +nifedipine or alpha methyl dopa +nifedipine +MgSO4 . 
 
 72
 The deadborn rate is relatively higher in antepartal eclampsia and 
intrapartal eclampsia while treating with alpha methyl dopa +nifedipine and 
alpha methyl dopa +nifedipine +MgSO4 as in antepartal mothers the cases 
treated with alpha methyl dopa  only had one deadborn (14.2%), treating 
with alpha methyl dopa +nifedipine the deadborn were 4(44.4%) and 
treating with alpha methyl dopa +nifedipine +MgSO4 the deadborn were 
21(61.7%). In intrapartal eclampsia, on treatment with alpha methyl dopa 
+nifedipine the deadborn cases was 1(50%). These datas show that  
 
the fetal outcome may not be dependent upon the mode of treatment. This 
may be due to the severity of the disease. 
 
 Livebirths were 361(68.1%) in cases and 483(78.5%) in control group 
when delivered via naturalis. When delivered via naturalis the deadborn 
babies were 98(88.3%) . In cases group whereas in control group all 
deadborn babies 45(100%) were delivered via naturalis. 
 
 This data shows that type of delivery does not have much impact on 
positive as well as negative fetal outcome.(refer table 17) 
 Out of 631 babies of cases group population whose gestational age 
and maturity were analysed, 171(27.1%) were delivered preterm, and 117 
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(18.5%)babies were delivered as term- small for gestational age, totaling 
288(45.6%). Out of 633 babies of control group, 18(2.8%) were delivered 
preterm, 74(11.7%) babies were delivered as term small for gestational age. 
This show the greater negative impact on fetal outcome in case group 
compared with control group. 
 
 524(82.8%) babies were born as term appropriate for gestational age 
in control group whereas 311(49.3%) babies were born as tern appropriate 
for age in case group. This also shows the negative impact on fetal outcome 
in case group compared with control group. 
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CONCLUSION 
 
 From the study, the following conclusions were made out. 
• Both maternal and fetal mortality were higher in hypertensive 
disorders complicating pregnancy. 
 
• Follow up of gestational induced hypertension cases and chronic 
hypertension cases is needed to detect superimposed preeclampsia. 
 
• Diagnosis of both newly diagnosed and recurrent cases occurs only in 
third trimester which has a greater negative impact on fetal outcome. 
 
• There is increased severity of the disorder in recurrent hypertensive 
disorders complicating pregnancy. 
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• There is no difference of severity of hypertensive disorders 
complicating pregnancy between primigravida. 
 
• With increasing severity of the hypertensive disorders complicating 
pregnancy the dead born babies were more in number. 
 
 
• The type of delivery does not have much impact both on positive as 
well as negative fetal outcome. 
 
• Preterm babies and term SGA were more in the case group which will 
have greater negative impact in the future wellbeing of the baby. 
 
• It has to be kept in mind that recurrent PIH still occurs. 
 
 
• Earlier diagnosis of the hypertensive disorders complicating 
pregnancy prevent the negative impact on fetal wellbeing which 
stresses the need of identification of cases not only by doctors but also 
other field health functionaries.  
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• PIH training unit can be established at every medical college like 
diarrhea treatment cum training unit for diarrhea and periodic 
continuing medical education on PIH can be conducted for field heath 
functionaries and doctors working in primary and secondary level 
institutions.  This will go in a long way to improve the fetal out come 
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              AGE DISTRIBUTION OF STUDY POPULATION 
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TYPE OF DIAGNOSIS OF CASES 
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MONTH OF DIAGNOSIS OF CASES 
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MONTH OF  DIAGNOSIS OF CASES  
AND  
THEIR FETAL OUTCOME 
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TYPE OF DIAGNOSIS  
IN RELATION TO CASE SEVERITY 
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GRAVIDA ASSESSMENT IN STUDY POPULATION 
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FETAL OUTCOME IN RELATION TO GRAVIDA 
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SEVERITY OF CASE GROUP 
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SEVERITY OF CASE GROUP IN RELATION TO 
GRAVIDA 
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FETAL OUTCOME OF CASES IN RELATION TO 
SEVERITY 
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FETAL OUTCOME IN STUDY POPULATION 
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DRUGS RECEIVED IN CASE POPULATION 
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FETAL OUTCOME IN RELATION TO DRUGS RECEIVED 
IN CASE POPULATION 
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FETAL OUTCOME IN RELATION TO TYPE OF 
DELIVERY IN STUDY POPULATION 
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FETAL OUTCOME WITH MATURITY IN STUDY 
POPULATION 
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